Related Experiment Video
Updated: Jun 2, 2026
08:27
Detection of Human Leukocyte Antigen Biomarkers in Breast Cancer Utilizing Label-free Biosensor Technology
Published on: March 24, 2015
Human complement factor H is a novel diagnostic marker for lung adenocarcinoma
Tiantian Cui1, Yuan Chen, Thomas Knösel
1Institute of Pathology, University Hospital Jena, Friedrich-Schiller-University Jena, Ziegelmühlenweg 1, Jena 07743, Germany.
International Journal of Oncology
|April 20, 2011
Summary
Human complement factor H (CFH) is expressed in non-small cell lung cancer cells and may serve as a diagnostic marker for lung adenocarcinoma, correlating with poorer prognosis.
Area of Science:
- Immunology
- Oncology
- Molecular Biology
Background:
- Human complement factor H (CFH) regulates complement activation.
- CFH may influence cancer cell resistance to complement-mediated lysis.
- Its role in human lung cancer requires further investigation.
Purpose of the Study:
- To investigate the role of CFH in human lung cancer.
- To analyze CFH expression in lung cancer cell lines and primary tumors.
- To evaluate CFH as a potential diagnostic marker for lung adenocarcinoma.
Main Methods:
- RT-PCR, Western blotting, and immunofluorescence for CFH expression in cell lines.
- Immunohistochemistry (IHC) on tissue microarray (TMA) for primary tumors.
- Flow cytometry to detect CFH binding to lung cancer cells.
Main Results:
- CFH mRNA detected in 6/10 non-small cell lung cancer (NSCLC) cell lines, not in small cell lung cancer (SCLC).
- CFH protein expressed in cytoplasm and membrane of 3 NSCLC cell lines.
- High CFH expression in 54/101 primary tumors, significantly correlated with lung adenocarcinoma (p=0.009).
- CFH-positive adenocarcinoma showed a trend towards worse prognosis (p=0.082) and shorter survival (<20 months, p=0.033).
Conclusions:
- NSCLC cells express and secrete CFH.
- CFH is significantly correlated with lung adenocarcinoma.
- CFH may represent a novel diagnostic marker for human lung adenocarcinoma.
